Published in Medical Letter on the CDC and FDA, September 10th, 2006
In the second quarter of 2006, Point achieved several important milestones. It continued enrollment into two randomized Phase III double blind placebo-controlled trials of talabostat in patients with metastatic non-small cell lung cancer (NSCLC) who have previously failed platinum based therapies. Each trial will enroll approximately four hundred patients. The first trial is evaluating docetaxel (Taxotere) with and without talabostat. The second randomized Phase III trial is studying pemetrexed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.